TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 235
- 试验地点
- 29
- 主要终点
- Peak 6-minute Walk Distance
研究概览
简要总结
This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.
详细描述
Patients who have been on a stable dose of 125 mg twice daily (bid) of bosentan or any stable dose of sildenafil for at least three months prior to study start were randomized to either treprostinil inhalation solution or matching placebo.
Administration of study medication was performed by inhalation with the OPTINEB™ ultrasonic nebulizer.
The proposed dosing regimen was four times daily-upon awakening, at midday, evening (dinner time) and bedtime.
After a patient has completed the twelve-week study period, they were given the option of enrolling into an open-label extension study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinically stable, pulmonary arterial hypertension diagnosed as either idiopathic or familial PAH, collagen vascular disease associated PAH, HIV PAH, or PAH induced by anorexigens, New York Heart Association (NYHA) Class III or Class IV.
- •Been on a stable dose of 125 mg twice daily (bid) of bosentan OR any stable dose of sildenafil for at least three months prior to study start
- •An unencouraged six minute walk test (6MWT) of between 200 and 450 meters at screening
- •Cardiac catheterization within the past 13 months consistent with PAH, specifically mean pulmonary artery pressure (PAPm) ≥25 mmHg (at rest), pulmonary capillary wedge pressure (PCWP) (or left ventricular end diastolic pressure) ≤15 mmHg, and pulmonary vascular resistance (PVR) >3 mmHg/L/min
- •Within the past 12 months, patients must have had a chest radiograph consistent with the diagnosis of PAH
- •Willing and able to follow all study procedures
排除标准
- •Considering pregnancy, are pregnant and/or lactating
- •PAH due to conditions other than noted in the above inclusion criteria.
- •Have had any change in or discontinued any PAH medication within the last three months, including but not limited to endothelin receptor antagonist (ERA), or calcium channel blockers (CCB) (with the exception of anticoagulants)
- •Have received any prostanoid within the 30 days before screening or are scheduled to receive any during the course of the study
- •Have received any investigational medication within 30 days prior to the start of this study or are scheduled to receive another investigational drug during the course of this study
- •Have a known intolerance to any drug, especially to treprostinil sodium or prostanoids
- •Have an increased risk of hemorrhage
- •Have a new type of chronic therapy (e.g., a different category of vasodilator, diuretic) for PAH added within the last month, except anticoagulants
- •Have any musculoskeletal disease or any other disease that would limit ambulation.
研究组 & 干预措施
Inhaled treprostinil
0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
干预措施: Inhaled treprostinil (Drug)
Placebo
Placebo inhalation solution for use in ultrasonic nebulizer
干预措施: Placebo inhalation solution (Drug)
结局指标
主要结局
Peak 6-minute Walk Distance
时间窗: 12 weeks
Change in peak 6-minute walk distance from baseline to Week 12. Peak 6MWD was defined as a 6-minute walk test (6MWT) within 10 to 60 minutes after study drug inhalation
次要结局
- New York Heart Association (NYHA) Functional Classification(12 weeks)
- N-terminal Pro-B-Type Natriuretic Peptide (NT Pro-BNP)(12 weeks)
- Borg Dyspnea Score(12 weeks)
- Clinical Worsening Events(12 weeks)
- Trough 6MWD at Week 12(12 Weeks)
- Peak 6MWD at Week 6(6 weeks)
- Quality of Life (Minnesota Living With Heart Failure)(12 weeks)
- Change in Signs and Symptoms of PAH(12 weeks)